Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stage III Rectal Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Stage III Rectal Cancer. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2009-016782-28 Sponsor Protocol Number: GMIHO-009/2009/AG52 Start Date*: 2010-09-15
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III)
    Medical condition: Locally advanced RAS wildtype rectal cancer (clinical stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001203-36 Sponsor Protocol Number: CI-IPOP.22-2012 Start Date*: 2014-02-07
    Sponsor Name:Instituto Português de Oncologia do Porto Francisco Gentil, EPE
    Full Title: Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer
    Medical condition: Rectal cancer stage II Rectal cancer stage III
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010093-38 Sponsor Protocol Number: HyRec Start Date*: 2012-08-15
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler
    Full Title: Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer
    Medical condition: Locally advanced primary or locally recurrent rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038051 Rectal cancer stage IV PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007177-23 Sponsor Protocol Number: Mo19051 Start Date*: 2008-11-12
    Sponsor Name:U.Z. Gasthuisberg
    Full Title: A randomized phase II of bevacizumab, capecitabine and radiation therapy with or without oxaliplatin in the preoperative treatment of locally advanced rectal cancer
    Medical condition: locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038049 Rectal cancer stage II LLT
    9.1 10038050 Rectal cancer stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000728-41 Sponsor Protocol Number: 06/02-29 jan'07 Start Date*: 2008-09-12
    Sponsor Name:Maastro clinic
    Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer
    Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038050 Rectal cancer stage III PT
    9.1 10038051 Rectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001347-29 Sponsor Protocol Number: Start Date*: 2004-09-17
    Sponsor Name:Odense University Hospital
    Full Title: Treatment of patients with locally advanced rectal cancer. TEGAFOX (UFT/leukovorin og Oxaliplatin) before, during and after curatively intended radiotherapy. A Danish phase I/II trial
    Medical condition: Locally advanced non-resectable rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.0 10038050 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000876-40 Sponsor Protocol Number: IJB-REGINA-2020 Start Date*: 2021-03-09
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancer
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006532-21 Sponsor Protocol Number: 40054-22062 Start Date*: 2008-10-27
    Sponsor Name:EORTC
    Full Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)
    Medical condition: locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005782-59 Sponsor Protocol Number: 08/0136 Start Date*: 2010-09-29
    Sponsor Name:University College London
    Full Title: ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006701-25 Sponsor Protocol Number: UCL/07/132 Start Date*: 2008-02-21
    Sponsor Name:University College London
    Full Title: EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer. (North West Clinical Oncology Group-04 on behalf of the NCRI rectal cancer subgroup)
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001206-29 Sponsor Protocol Number: ShorTrip Start Date*: 2021-07-22
    Sponsor Name:Fondazione GONO
    Full Title: ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer.
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003057-42 Sponsor Protocol Number: CAO/ARO/AIO-16 Start Date*: 2018-02-23
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000847-25 Sponsor Protocol Number: EMR63325-013 Start Date*: 2011-07-04
    Sponsor Name:Merck KGaA
    Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch...
    Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10038043 Rectal cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000876-14 Sponsor Protocol Number: ACO/ARO/AIO-18.1 Start Date*: 2020-01-21
    Sponsor Name:University Hospital Frankfurt, Goethe University
    Full Title: ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal canc...
    Medical condition: Locally advanced rectal cancer (UICC stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002715-21 Sponsor Protocol Number: AIO-KRK-0220 Start Date*: 2021-10-22
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage II high risk or stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study (ANT...
    Medical condition: Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (s...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009966 Colon carcinoma stage III LLT
    22.0 10010331 - Congenital, familial and genetic disorders 10078672 DNA mismatch repair protein gene mutation PT
    21.0 10010331 - Congenital, familial and genetic disorders 10080676 Microsatellite instability LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001171 Adenocarcinoma of colon stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007446 Carcinoma of rectum LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007450 Carcinoma of rectum stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007468 Carcinoma rectum stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003289-18 Sponsor Protocol Number: 219369 Start Date*: 2023-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
    Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022754-17 Sponsor Protocol Number: UCL/09/0176 Start Date*: 2012-08-22
    Sponsor Name:University College London
    Full Title: Bevacizumab And Combination Chemotherapy in rectal cancer Until Surgery: A Phase II, Multicentre, Open-label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defin...
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000414-41 Sponsor Protocol Number: PROICM2021-01GRE Start Date*: 2021-07-19
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy
    Medical condition: Locally advanced rectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007450 Carcinoma of rectum stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006646-34 Sponsor Protocol Number: ERA-GASTRO-ONCO-001 Start Date*: 2007-03-13
    Sponsor Name:Erasme Hospital - Department of Gastroenterology
    Full Title: OXALIPLATIN PLUS 5-FLUOROURACIL BASED-CHEMOTHERAPY INDUCTION FOLLOWED BY PREOPERATIVE CHEMORADIATION VERSUS PREOPERATIVE CHEMORADIATON ALONE IN ADVANCED RECTAL ADENOCARCINOMA: RANDOMIZED CONTROLLED...
    Medical condition: advanced rectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038028 Rectal adenocarcinoma stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000802-30 Sponsor Protocol Number: ML18522 Start Date*: 2005-09-15
    Sponsor Name:ROCHE
    Full Title: Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.
    Medical condition: Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 02:41:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA